Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The morning after

Sorry, I sent the posting out last night before I completed the intro. I'm talking about "The Morning After" the upcoming April Q report and the fact that, even after a strong SP increase, volitility could remain high.

Re Your question; Name one thing significant we know:

(partial list)

- PTSC has been making money for past year and their product is recession proof with hundreds of customers in the wings.

- Good cash position and no debt.

- Relatively transparent books.

This is more than we know about many high flying companies.

Again: Reasons volitility could remain high after a good April Q report:

PTSC volitility could be driven by 3 factors:

- significant variations in future Q EPS (likely)

- uncertainty of the financial impact of an aquisition, near & long term (likely)

- uncertainty of new litigation (less likely to significantly impact SP)

Share
New Message
Please login to post a reply